Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been
studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable …

Interferon-gamma (IFN-γ) is a pleiotropic molecule with associated antiproliferative, pro-
apoptotic and antitumor mechanisms. This effector cytokine, often considered as a major …

With more than 20 molecules in clinical use, monoclonal antibodies have finally come of age
as therapeutics, generating a market value of 11billionin2004,expectedtoreach 26 billion by …

With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …

Abstract Treatment of cancer is a double-edged sword: it should be as aggressive as
possible to completely destroy the tumour, but it is precisely this aggressiveness which often …

Indoleamine 2, 3-dioxygenase (EC 1.13. 11.42) is a heme-containing dioxygenase which
catalyzes the first and rate-limiting step in the major pathway of l-tryptophan catabolism in …

The remarkable clinical success of immune-checkpoint inhibitors for the treatment of a
growing number of cancer types has sparked interest in the discovery of novel forms of …

The alternatively spliced extra‐domain B of fibronectin is one of the best characterized
markers of tumor angiogenesis. Similarly, the extra‐domain A (EDA), which can also be …

During cancer progression, the extracellular matrix (ECM) of the tissue in which the tumor
grows is extensively remodeled, both by degradation of preexisting ECM molecules and by …